MQS Management LLC Acquires Shares of 837 Intuitive Surgical, Inc. (NASDAQ:ISRG)

MQS Management LLC bought a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) during the third quarter, Holdings Channel.com reports. The fund bought 837 shares of the medical equipment provider’s stock, valued at approximately $411,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Hazlett Burt & Watson Inc. grew its stake in shares of Intuitive Surgical by 5.8% in the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock worth $177,000 after acquiring an additional 20 shares during the last quarter. Mitchell Mcleod Pugh & Williams Inc. raised its holdings in Intuitive Surgical by 4.1% in the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock worth $247,000 after buying an additional 20 shares during the last quarter. Ullmann Wealth Partners Group LLC lifted its stake in shares of Intuitive Surgical by 1.6% in the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after buying an additional 21 shares in the last quarter. One Wealth Management Investment & Advisory Services LLC grew its holdings in shares of Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after buying an additional 23 shares during the last quarter. Finally, Falcon Wealth Planning increased its position in shares of Intuitive Surgical by 0.4% during the third quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider’s stock valued at $2,797,000 after acquiring an additional 23 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ISRG. BTIG Research set a $535.00 price target on Intuitive Surgical in a research note on Friday, October 18th. Robert W. Baird boosted their target price on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a report on Friday, October 18th. Wells Fargo & Company increased their price objective on shares of Intuitive Surgical from $466.00 to $549.00 and gave the company an “overweight” rating in a research report on Friday, October 18th. Finally, Leerink Partners raised their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Insider Transactions at Intuitive Surgical

In related news, SVP Henry L. Charlton sold 40,243 shares of Intuitive Surgical stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jamie Samath sold 22,903 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $525.00, for a total value of $12,024,075.00. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at $4,597,425. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 91,178 shares of company stock valued at $45,897,071 over the last 90 days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Trading Down 0.1 %

Intuitive Surgical stock opened at $536.69 on Thursday. Intuitive Surgical, Inc. has a 12-month low of $287.98 and a 12-month high of $542.59. The firm has a market capitalization of $191.16 billion, a price-to-earnings ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. The firm has a 50 day moving average of $495.85 and a 200 day moving average of $455.08.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, beating the consensus estimate of $1.24 by $0.32. The firm had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. On average, analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.